标题
DPP-4 inhibitors: pharmacological differences and their clinical implications
作者
关键词
-
出版物
Expert Opinion On Drug Safety
Volume 13, Issue sup1, Pages 57-68
出版商
Informa Healthcare
发表日期
2014-08-29
DOI
10.1517/14740338.2014.944862
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Meta-Analysis of the Cardiovascular Outcomes with Dipeptidyl Peptidase 4 Inhibitors: Validation of the Current FDA Mandate
- (2014) Shikhar Agarwal et al. American Journal of Cardiovascular Drugs
- Effect of metabolic syndrome and its components on prostate cancer risk: Meta-analysis
- (2014) K. Esposito et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials
- (2014) M. Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors
- (2013) M. Barbieri et al. ATHEROSCLEROSIS
- A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
- (2013) Mika Nabeno et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy
- (2013) Anthony H. Barnett et al. CLINICAL DRUG INVESTIGATION
- Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial
- (2013) Julio Rosenstock et al. Diabetes & Vascular Disease Research
- Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study
- (2013) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring
- (2013) Y. L. He et al. DIABETES OBESITY & METABOLISM
- Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real-life worldwide observational study (EDGE)
- (2013) C. Mathieu et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Fracture Risk and Bone Mineral Density in Metabolic Syndrome: A Meta-Analysis
- (2013) Katherine Esposito et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats
- (2013) Wulan Bao et al. JOURNAL OF VASCULAR SURGERY
- Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study
- (2013) W David Strain et al. LANCET
- Metabolic syndrome and postmenopausal breast cancer
- (2013) Katherine Esposito et al. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
- Cardiovascular effects of gliptins
- (2013) André J. Scheen Nature Reviews Cardiology
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)
- (2012) Masaya Sakamoto et al. Cardiovascular Diabetology
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition
- (2012) Swenja Kröller-Schön et al. CARDIOVASCULAR RESEARCH
- Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: Results from the randomized Optima study
- (2012) B. Guerci et al. DIABETES & METABOLISM
- Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition
- (2012) M. R. Rizzo et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2013
- (2012) DIABETES CARE
- Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus
- (2012) W. Kothny et al. DIABETES OBESITY & METABOLISM
- Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats
- (2012) Sayaka Maeda et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Impact of glycemic variability on cardiovascular outcomes beyond glycated hemoglobin. Evidence and clinical perspectives
- (2012) F. Picconi et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Acute Exposure to Low Glucose Rapidly Induces Endothelial Dysfunction and Mitochondrial Oxidative Stress
- (2011) Jingli Wang et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
- (2011) Kathleen R. Richard et al. CLINICAL THERAPEUTICS
- Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus
- (2011) Jean Doucet et al. CURRENT MEDICAL RESEARCH AND OPINION
- DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
- (2011) A.J. Scheen DIABETES & METABOLISM
- Postprandial Hyperglycemia and Glycemic Variability: Should we care?
- (2011) E. Standl et al. DIABETES CARE
- The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an "Endothelial Resistance" to Glucagon-Like Peptide 1 in Diabetes
- (2011) A. Ceriello et al. DIABETES CARE
- Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase
- (2011) M. J. Willemen et al. DIABETES CARE
- Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
- (2011) J. J. Holst et al. DIABETES CARE
- Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial
- (2011) V. Lukashevich et al. DIABETES OBESITY & METABOLISM
- Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
- (2011) B. Ahrén et al. DIABETES OBESITY & METABOLISM
- Glycemic Variability: Measurement and Utility in Clinical Medicine and Research—One Viewpoint
- (2011) David Rodbard Diabetes Technology & Therapeutics
- Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs
- (2011) K. R. Hjøllund et al. DIABETOLOGIA
- Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells
- (2011) B. Schisano et al. DIABETOLOGIA
- Pharmacology of Dipeptidyl Peptidase-4 Inhibitors
- (2011) Roberta Baetta et al. DRUGS
- A review of gliptins in 2011
- (2011) André J Scheen EXPERT OPINION ON PHARMACOTHERAPY
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes
- (2011) Y.-L. He et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
- (2011) L. Cai et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis
- (2011) Takanori Matsui et al. PHARMACOLOGICAL RESEARCH
- Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
- (2010) Michael A. Nauck AMERICAN JOURNAL OF MEDICINE
- Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A
- (2010) Hisko Oeseburg et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Oxidative Stress and Diabetic Complications
- (2010) Ferdinando Giacco et al. CIRCULATION RESEARCH
- Dipeptidylpeptitase-4 Inhibitors (Gliptins)
- (2010) André J. Scheen CLINICAL PHARMACOKINETICS
- Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study
- (2010) S. Arnolds et al. DIABETES CARE
- Effects of Acute Hypoglycemia on Inflammatory and Pro-atherothrombotic Biomarkers in Individuals With Type 1 Diabetes and Healthy Individuals
- (2010) N. Gogitidze Joy et al. DIABETES CARE
- Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
- (2010) B. Ahren et al. DIABETES CARE
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
- (2010) A. J. Scheen DIABETES OBESITY & METABOLISM
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial
- (2010) P. Hollander et al. DIABETES OBESITY & METABOLISM
- ‘Glycaemic variability’: a new therapeutic challenge in diabetes and the critical care setting
- (2010) A. Ceriello et al. DIABETIC MEDICINE
- Vildagliptin
- (2010) Gillian M. Keating DRUGS
- Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes
- (2010) Antonio Ceriello EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION
- The glucose triad and its role in comprehensive glycaemic control: current status, future management
- (2010) A. Ceriello INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Endogenous GLP-1 Regulates Postprandial Glycemia in Humans: Relative Contributions of Insulin, Glucagon, and Gastric Emptying
- (2010) Mathias Nicolaus et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes
- (2009) Shrikanth H. Havale et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
- (2009) Mark Kirby et al. CLINICAL SCIENCE
- The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
- (2009) R. A. DeFronzo et al. DIABETES CARE
- Diagnosis and Classification of Diabetes Mellitus
- (2009) DIABETES CARE
- Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia
- (2009) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
- (2009) T. Heise et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
- (2009) T. Vilsbøll et al. DIABETES OBESITY & METABOLISM
- Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes
- (2009) Bo Ahrén et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations
- (2009) Raffaele Marfella et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
- (2009) Joshua J. Neumiller JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION
- Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
- (2009) E.J. Verspohl PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
- (2008) R CHRISTOPHER et al. CLINICAL THERAPEUTICS
- Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
- (2008) Itamar Raz et al. CURRENT MEDICAL RESEARCH AND OPINION
- Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients
- (2008) A. Ceriello et al. DIABETES
- Characterizing Glucose Exposure for Individuals with Normal Glucose Tolerance Using Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis
- (2008) Roger S. Mazze et al. Diabetes Technology & Therapeutics
- Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes
- (2008) Nasser Mikhail EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Sustained Efficacy and Reduced Hypoglycemia during One Year of Treatment with Vildagliptin Added to Insulin in Patients with Type 2 Diabetes Mellitus
- (2008) V. Fonseca et al. HORMONE AND METABOLIC RESEARCH
- Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Chinese Volunteers
- (2008) Pei Hu et al. JOURNAL OF CLINICAL PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search